Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB versus SCEMBLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB versus SCEMBLIX.
BOSUTINIB vs SCEMBLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that inhibits the BCR-ABL kinase, including many imatinib-resistant mutations, and Src family kinases.
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
400 mg orally once daily with food.
200 mg orally once daily with a meal.
None Documented
None Documented
Terminal elimination half-life approximately 33 hours (range 22-60 hr) after oral administration, supporting once-daily dosing.
Clinical Note
moderateBosutinib + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Bosutinib."
Clinical Note
moderateBosutinib + Digitoxin
"Bosutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBosutinib + Deslanoside
"Bosutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBosutinib + Acetyldigitoxin
"Bosutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing.
Primarily fecal (approx. 68% as unchanged drug and metabolites) and renal (approx. 25%, with <0.2% as unchanged drug in urine).
Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor, Antineoplastic